

Application No.: 10/731,811
 Supplemental Amdt. Dated: November 3, 2005

Attorney Docket No. BRV.10017
 Page 2 of 6


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (Canceled).

Claim 2 (Previously Presented): A morpholino-nucleotide of the formula:



wherein R¹ represents a nucleic base, m is 0 or 1, and R² is selected from the group consisting of:

-(CH₂)_n-SR³, -(CH₂)_n-CO-R³, and -(CH₂)_n-OR³

in which n is an integer ranging from 1 to 12 and R³ is selected from the group consisting of a label, a protein, an enzyme, a fatty acid, and a peptide.

Claim 3 (Previously Presented): The morpholino-nucleotide of claim 2 wherein R¹ is a natural nucleic base selected from the group consisting of adenine, guanine, cytosine, thymine, uracil, xanthine, hypoxanthine, and 2-aminopurine.

Claim 4 (Previously Presented): The morpholino-nucleotide of claim 2 wherein R¹ is selected from the group consisting of:



Application No.: 10/731,811
 Supplemental Amdt. Dated: November 3, 2005

Attorney Docket No. BRV.10017
 Page 3 of 6

Claim 5 (Previously Presented): The morpholino-nucleotide of claim 2 wherein R³ is a label selected from the group consisting of radioactive products, luminescent products, electroluminescent and fluorescent products, and enzymatic labels.

Claim 6 (Previously Presented): The morpholino-nucleotide of claim 5 wherein R¹ is a natural nucleic base selected from the group consisting of adenine, guanine, cytosine, thymine, uracil, xanthine, hypoxanthine, and 2-aminopurine.

Claim 7 (Previously Presented): The morpholino-nucleotide of claim 2 wherein R³ is a fluorophore.


Claim 8 (Previously Presented): The morpholino-nucleotide of claim 7 wherein R¹ is a natural nucleic base selected from the group consisting of adenine, guanine, cytosine, thymine, uracil, xanthine, hypoxanthine, and 2-aminopurine.

Claim 9 (Previously Presented): The morpholino-nucleotide of claim 2 wherein R³ is selected from the group consisting of fluorescein, biotin, and rhodamine.

Claim 10 (Previously Presented): The morpholino-nucleotide of claim 9 wherein R¹ is a natural nucleic base selected from the group consisting of adenine, guanine, cytosine, thymine, uracil, xanthine, hypoxanthine, and 2-aminopurine.

Claim 11 (Previously Presented): The morpholino-nucleotide of claim 2 wherein m is 0.

Claim 12 (Previously Presented): A morpholino-nucleotide of the formula:



Application No.: 10/731,811
Supplemental Amdt. Dated: November 3, 2005

Attorney Docket No. BRV.10017
Page 4 of 6

wherein R¹ is a natural nucleic base selected from the group consisting of guanine, cytosine, thymine, uracil, xanthine, hypoxanthine, and 2-aminopurine; m is 0 or 1; and R² is selected from the group consisting of:

-(CH₂)_n-NH-R³, -(CH₂)_n-SR³, -(CH₂)_n-CO-R³, and -(CH₂)_n-OR³

in which n is an integer ranging from 1 to 12 and R³ is selected from the group consisting of a label, a protein, an enzyme, a fatty acid, and a peptide.


Claim 13 (Previously Presented): The morpholino-nucleotide of claim 12 wherein R³ is a label selected from the group consisting of radioactive products, luminescent products, electroluminescent and fluorescent products, and enzymatic labels.

Claim 14 (Previously Presented): The morpholino-nucleotide of claim 12 wherein R³ is a fluorophore.

Claim 15 (Previously Presented): The morpholino-nucleotide of claim 12 wherein R³ is selected from the group consisting of fluorescein, biotin, and rhodamine.

Claim 16 (Previously Presented): The morpholino-nucleotide of claim 12 wherein m is 0.

Claim 17 (Previously Presented): A morpholino-nucleotide of formula I:



wherein R¹ is a nucleic base selected from the group consisting of adenine, guanine, cytosine, and thymine; R² is -(CH₂)₄-NH-R³; and R³ is -C(S)-NH-fluorescein.

NOV-03-2005 16:28 From:HUTCH&MASON PATENT

919 829 4332

To:USPTO

P.8/9

Application No.: 10/731,811
Supplemental Amdt. Dated: November 3, 2005

Attorney Docket No. BRV.10017
Page 5 of 6

Claims 18-32 (Cancelled).